It has been shown that cannabidiol (CBD), a cannabinoid with very low affinity for CB1 and CB2, has protective effects in murine colitis as observed by a reduction of colon injury, inducible nitric oxide synthase expression, reactive oxygen species production, MPO activity, and tumor necrosis factor alpha (TNF-α) levels [17–21]. Here, MPO is linked to colitis.